Bellevue Group AG Buys Glaukos Corp, Arvinas Inc, Becton, Dickinson and Co, Sells Celgene Corp, Gilead Sciences Inc, Teladoc Health Inc

• New Purchases: ARVN, PACB, MYL, TXG, SDC, HCAT, BIO, XLRN, ZGNX, TEVA, PTLA, JNJ, CRL, MNTA, LVGO, LIN, PAYX, CLX, STML, XLNX, ADMS,
• Added Positions: IONS, GKOS, AGIO, BDX, ABT, INSM, NKTR, UNH, MGNX, TFX, ALDR, ESPR, WMGI, SYK, ALGN, ZBH, CDNA, EVH, MYOV, BMY, CI, EW, BAX, FIXX, ISRG, ALNY, ARGX, DHR, HCM, INSP, MDT, ALXN, CVS, HCA, ITCI, AMGN, MRNA, SRRK, BOLD, BSX, HZNP, MYOK, TNDM, CRSP, GTHX, GMED, PODD, IART, OXFD, VCRA, BIIB, CNC, CHRS, XRAY, DXCM, HSIC, HMSY, HOLX, IDXX, INGN, IRTC, KURA, LIVN, MASI, MOH, NVRO, OMCL, RMD, SGEN, SQM, TRHC, VNE, WVE, ADBE, AXP, ADI, ALV, AUTL, AVTR, BNFT, BPMC, BKNG, BR, BF.B, CERN, CBPO, CL, TCOM, DPZ, EA, ENTG, FAST, FATE, GGG, HTHT, IBKR, ICE, XENT, IPGP, JD, KEX, LYV, MTB, MKL, MKC, MTD, MCHP, MCO, POL, POOL, QTRX, QTNT, RGNX, SPGI, ST, SWAV, SILK, SWKS, TRMB, QURE, VAR, VEEV, VRSN, WAB, WSO,
• Reduced Positions: CELG, GILD, NBIX, TDOC, ANTM, ILMN, QDEL, FIT, QGEN, HALO, SAGE, HRC, ZLAB, BGNE, GH, CHNG, SUPN, A, ARNA, MRTX, ABMD, ACAD, ASND, MDCO, ICPT, GNMK, GWPH, PTCT, MCK, AGN, LH,
• Sold Out: AVDR, BLUE, CSLT, FOLD, ANAB, RARE, WCG, AFMD, MELI, BIS, CRM, USB, VKTX,

For the details of Bellevue Group AG's stock buys and sells, go to https://www.gurufocus.com/guru/bellevue+group+ag/current-portfolio/portfolio

1. Ionis Pharmaceuticals Inc (IONS) - 8,321,914 shares, 9.28% of the total portfolio. Shares added by 4.58%
2. Neurocrine Biosciences Inc (NBIX) - 3,298,474 shares, 5.53% of the total portfolio. Shares reduced by 6.99%
3. Incyte Corp (INCY) - 3,696,200 shares, 5.11% of the total portfolio. Shares reduced by 0.04%
4. Vertex Pharmaceuticals Inc (VRTX) - 1,429,139 shares, 4.51% of the total portfolio. Shares added by 0.61%
5. Sage Therapeutics Inc (SAGE) - 1,303,504 shares, 3.41% of the total portfolio. Shares reduced by 1.35%

Bellevue Group AG initiated holding in Arvinas Inc. The purchase prices were between $21.55 and $27.61, with an estimated average price of $24.57. The stock is now traded at around $30.04. The impact to a portfolio due to this purchase was 0.32%. The holding were 806,403 shares as of .

Bellevue Group AG initiated holding in Pacific Biosciences of California Inc. The purchase prices were between $4.99 and $6.16, with an estimated average price of $5.6. The stock is now traded at around $4.72. The impact to a portfolio due to this purchase was 0.23%. The holding were 2,373,787 shares as of .

Bellevue Group AG initiated holding in Mylan NV. The purchase prices were between $17.61 and $22.53, with an estimated average price of $19.61. The stock is now traded at around $17.26. The impact to a portfolio due to this purchase was 0.11%. The holding were 293,200 shares as of .

Bellevue Group AG initiated holding in 10x Genomics Inc. The purchase prices were between $49.99 and $62, with an estimated average price of $55.34. The stock is now traded at around $63.50. The impact to a portfolio due to this purchase was 0.09%. The holding were 100,000 shares as of .

Bellevue Group AG initiated holding in SmileDirectClub Inc. The purchase prices were between $12.94 and $19.48, with an estimated average price of $16.68. The stock is now traded at around $8.89. The impact to a portfolio due to this purchase was 0.09%. The holding were 350,000 shares as of .

Bellevue Group AG initiated holding in Health Catalyst Inc. The purchase prices were between $30.31 and $48.63, with an estimated average price of $39.37. The stock is now traded at around $33.74. The impact to a portfolio due to this purchase was 0.09%. The holding were 160,216 shares as of .

Bellevue Group AG added to a holding in Glaukos Corp by 275.02%. The purchase prices were between $58.58 and $83.91, with an estimated average price of $70.45. The stock is now traded at around $62.70. The impact to a portfolio due to this purchase was 0.34%. The holding were 402,148 shares as of .

Bellevue Group AG added to a holding in Becton, Dickinson and Co by 34.16%. The purchase prices were between $236.34 and $262.48, with an estimated average price of $253.08. The stock is now traded at around $248.80. The impact to a portfolio due to this purchase was 0.24%. The holding were 200,827 shares as of .

Bellevue Group AG added to a holding in Insmed Inc by 92.03%. The purchase prices were between $15.49 and $25.78, with an estimated average price of $19.36. The stock is now traded at around $19.21. The impact to a portfolio due to this purchase was 0.19%. The holding were 1,191,480 shares as of .

Bellevue Group AG added to a holding in UnitedHealth Group Inc by 22.80%. The purchase prices were between $215.26 and $266.65, with an estimated average price of $241.24. The stock is now traded at around $255.83. The impact to a portfolio due to this purchase was 0.18%. The holding were 238,712 shares as of .

Bellevue Group AG added to a holding in Nektar Therapeutics Inc by 20.52%. The purchase prices were between $16.91 and $36.27, with an estimated average price of $24.52. The stock is now traded at around $19.43. The impact to a portfolio due to this purchase was 0.18%. The holding were 3,172,886 shares as of .

Bellevue Group AG added to a holding in Teleflex Inc by 60.78%. The purchase prices were between $329.13 and $371.65, with an estimated average price of $348.57. The stock is now traded at around $342.38. The impact to a portfolio due to this purchase was 0.14%. The holding were 59,114 shares as of .

Bellevue Group AG sold out a holding in Avedro Inc. The sale prices were between $16.31 and $26.86, with an estimated average price of $21.72.

Bellevue Group AG sold out a holding in bluebird bio Inc. The sale prices were between $91.82 and $143.74, with an estimated average price of $117.86.

Bellevue Group AG sold out a holding in Castlight Health Inc. The sale prices were between $1.38 and $3.23, with an estimated average price of $2.

Bellevue Group AG sold out a holding in Amicus Therapeutics Inc. The sale prices were between $8.02 and $13.25, with an estimated average price of $10.87.

Bellevue Group AG sold out a holding in AnaptysBio Inc. The sale prices were between $34.99 and $56.19, with an estimated average price of $47.59.

Bellevue Group AG sold out a holding in WellCare Health Plans Inc. The sale prices were between $259.17 and $293.48, with an estimated average price of $275.99.